Sorry, you need to enable JavaScript to visit this website.
跳转到主要内容


孟鲁司特钠

孟鲁司特钠
CAS Number: 151567-02-1

孟鲁司特钠

治疗类别
抗过敏/抗哮喘
API技术
合成
剂型
口服固体制剂
瑞迪博士研发状态
可得到
注册备案情况
USA
Canada
CEP
Europe
China
Australia
New Zealand
Saudi Arabia
Israel
Indonesia
Brazil
创新品牌(美国)
SINGULAIR

Mechanism of Action

The cysteinyl leukotrienes (LTC4, LTD4, LTE4) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both early-and late-phase reactions and are associated with symptoms of allergic rhinitis.

Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT1 receptor (in preference to other pharmacologically important airway receptors, such as the prostanoid, cholinergic, or β-adrenergic receptor). Montelukast inhibits physiologic actions of LTD4 at the CysLT1 receptor without any agonist activity.

Indication

SINGULAIR is a leukotriene receptor antagonist indicated for:

  • Prophylaxis and chronic treatment of asthma in patients 12 months of age and older
  • Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older
  • Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2 years of age and older, and perennial allergic rhinitis (PAR) in patients 6 months of age and older

Dr. Reddy's的专长

Dr. Reddy's总部位于印度海得拉巴,是全球领先的活性药物成分(API)供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。

Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API(如类固醇,多肽,复杂长链分子和高效API(HPAPI /肿瘤药物))方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准,从而为这一专业知识提供补充。 Dr. Reddy's博士 孟鲁司特钠 API是研发,知识产权和监管方面广泛专业知识的结果。

帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量,安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化,从而避免短缺并满足需求的突然激增。

联系我们

请填写以下表格,我们会尽快与您联系

给我们发电子邮件: api@drreddys.com |   +91 40 49002253

免责声明

受有效专利保护的产品不得在销售此类产品构成专利侵权的国家/地区销售。可获得性可能仅限于某些市场或国家/地区。有关可获得性和产品适用性的更多信息,请 我们联系 .

所有产品信息,包括有关活性药物成分(API)、适应症和可能的作用机制的信息均基于公开的产品标签。

给我们发电子邮件: api@drreddys.com | +91 40 49002253